PLAQUE PSORIASIS

This study looks at the long-term safety and effectiveness of the drug ORKA-001 for adults with moderate-to-severe plaque psoriasis. Participants must have completed a previous Oruka Therapeutics study. The main goal is to track side effects, while also checking how well the drug…

This study tests an oral medication called deucravacitinib in teenagers aged 12 to 17 with moderate to severe plaque psoriasis. The goal is to see if the drug can clear or nearly clear skin and reduce itching compared to a placebo. About 366 participants will take the drug or a d…

This study tests a new oral drug, D-2570, in 477 adults with moderate to severe plaque psoriasis. Participants will receive either D-2570, a placebo, or an active comparator to see how well it clears skin and improves quality of life. The trial is double-blind, meaning neither pa…

This study tests a new cream called MC2-01 for plaque psoriasis, a skin condition causing red, scaly patches. About 537 adults in China will use the cream daily for 8 weeks to see if it clears skin better than a standard gel or a placebo. The goal is to find a safe and effective …

This study tests whether a newer pill (deucravacitinib) is safer for the heart than an older injected drug (ustekinumab) in people with moderate-to-severe plaque psoriasis. About 3,040 adults who also have heart risk factors like smoking, high blood pressure, or diabetes will tak…

This study tests a daily pill called zasocitinib in children and teens aged 4 to 17 with moderate-to-severe plaque psoriasis. The goal is to see if it safely clears or nearly clears skin patches. The trial lasts up to 4 years, with some participants starting on a placebo before s…

This study tests an oral medication called deucravacitinib in children aged 4 to 17 with moderate to severe plaque psoriasis. The goal is to find the right dose and see if it safely clears skin and reduces symptoms. Participants will be followed for up to 5 years to monitor long-…

This study tests an experimental drug called D-2570 against a placebo in 390 adults with moderate to severe plaque psoriasis. The main goal is to see if D-2570 can clear at least 90% of skin plaques after 16 weeks of treatment. Participants must have stable psoriasis for 6 months…

This study tests a new oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. About 140 adults aged 18-70 will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75%.

This study tests an experimental drug called ICP-332 against a placebo in 172 adults with moderate-to-severe plaque psoriasis. The main goal is to see if the drug can reduce psoriasis symptoms by at least 75% after 12 weeks. Participants must have had psoriasis for at least 6 mon…

This study tests whether adding two simple questions about morning stiffness and lower back pain to a standard screening tool can help doctors spot psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults in Canada who are candidates for bi…

This study tests an experimental drug called ORKA-001 in 160 adults with moderate-to-severe plaque psoriasis. Participants receive either the drug or a placebo to see if it can clear skin lesions. The main goal is to measure complete skin clearance after 16 weeks of treatment.

This study looks at whether taking vitamin D pills along with using a steroid cream (triamcinolone) can improve mild to moderate psoriasis better than the cream alone. About 24 adults will use the cream for 4 weeks, then be split into two groups: one gets vitamin D, the other a p…

This study tests an experimental pill called CS32582 for adults with moderate to severe plaque psoriasis. It has two parts: a small dose-finding phase and a larger 12-week treatment phase. The goal is to see if the drug safely reduces skin symptoms like redness and scaling. About…

This study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will measure changes in quality of life, focusing on skin symptoms and daily impacts, over up to 2.5 years. The goal is to see how well the …

This early-stage study tests whether a new tablet called UA026 is safe and how it works in the body. It involves 124 people, including healthy volunteers and those with moderate to severe plaque psoriasis. The goal is to find the right dose and check for side effects, not yet to …

This study tests a new medicine called ORKA-002 for people with moderate-to-severe plaque psoriasis. About 160 adults will receive either the drug or a placebo to see if it can clear skin and reduce symptoms. The goal is to find the best dose and check for side effects.

This study collects skin samples from people with conditions like acne, eczema, and psoriasis, as well as healthy volunteers. The goal is to analyze genes and other markers to better understand what causes these inflammatory skin diseases. No treatment is given; it is purely for …